Pharma BD Deal Intelligence
Karyopharm Therapeutics filed voluntary Chapter 11 petitions in the US Bankruptcy Court for the Southern District of Texas (Houston Division) on 2 November 2026 and simultaneously entered a Restructuring Support Agreement providing for a merger between Ayrmid Ltd. and a reorganized Karyopharm. The RSA was signed by lenders and noteholders holding 100% of funded debt, certain Revenue Interest Financing Agreement investors, holders of the 0% Series A Convertible Perpetual Preferred Stock, and Ayrmid, which serves as stalking horse bidder with a 3% break-up fee and expense reimbursement capped at 1% of the bid protection base. Under the merger terms, funded debt holders and DIP lenders would receive 100% of the common stock of the reorganized company, exchanged substantially concurrently for 55% of NewCo common stock, with Ayrmid shareholders holding 45%. Existing Karyopharm common and preferred stock receive no distribution and are to be cancelled; funded debt holders also receive contingent value rights tied to future XPOVIO net sales in myelofibrosis. The company secured a $110 million superpriority senior secured DIP facility comprising up to $55 million of new money loans plus roll-up loans. No purchase price is disclosed, so deal_value_usd_mm is left NULL. NOTE: ingested at pending_review by bd-enrichment-2026-11-04.
← Browse all deals · How we score deals
More: 2026 deals